NEJM published phase 1b results of gene therapy VERVE-102: LDL reduction by 62% after a single injection. Analysis of efficacy, risks, and prospects for patients with hypercholesterolemia. Read more.
Single infusion of VERVE-201 sustainably lowers LDL by more than 60%. Learn how CRISPR editing is changing the hypercholesterolemia therapy market. Read the analysis.
Phase 1 results of VERVE-102: sustained LDL-C reduction up to 62% in patients with hypercholesterolemia. Analysis of market implications and forecasts. Read more.
Journal NEJM published data on the drug VERVE-102: a single CRISPR injection (base editing) reduces LDL by 62% for 18 months without serious side effects. Learn details about the revolutionary therapy.
New AAV8 gene therapy NGGT006 for homozygous familial hypercholesterolemia reduced LDL-C by 97.5% in 3 weeks. Effect persists for 52 weeks. Find out who is eligible for treatment.